Johnson Johnson

Second Quarter 2022 Other Financial Disclosures Table of Contents

Table 1: Sales by Segment	1
Table 2: Sales by Geographic Area	2
Table 3: Sales of Key Products/Franchises	3 - 8
Table 3a: Supplemental Sales Reconciliation	9
Table 4: Condensed Consolidated Statement of Earnings - QTD	10
Table 5: Condensed Consolidated Statement of Earnings - YTD	11
Table 6: Non-GAAP Adjusted Operational Sales Growth - QTD	12
Table 7: Non-GAAP Adjusted Operational Sales Growth - YTD	13
Table 8: Non-GAAP Adjusted Net Earnings	14
Table 9: Non-GAAP IBT by Segment - QTD	15
Table 10: Non-GAAP IBT by Segment - YTD	16
Table 11: Non-GAAP P&L Reconciliation	17

Johnson & Johnson and Subsidiaries

Supplementary Sales Data

(Unaudited; Dollars in Millions)		SE	COND QUARTE	R				SIX MONTHS		
				Percent Change					Percent Change	
	2022	2021	Total	Operations	Currency	2022	2021	Total	Operations	Currency
Sales to customers by										
segment of business										
Consumer Health (1)										
U.S.	\$ 1,687	1,751	(3.6) %	(3.6)	-	\$ 3,244	3,362	(3.5) %	(3.5)	-
International	2,118	2,103	0.6	7.3	(6.7)	4,147	4,133	0.3	5.7	(5.4)
	3,805	3,854	(1.3)	2.3	(3.6)	7,391	7,495	(1.4)	1.6	(3.0)
Pharmaceutical (1)										
U.S.	7,159	6,869	4.2	4.2	-	13,791	13,315	3.6	3.6	-
International	6,158	5,611	9.8	22.1	(12.3)	12,395	11,266	10.0	19.4	(9.4)
	13,317	12,480	6.7	12.3	(5.6)	26,186	24,581	6.5	10.8	(4.3)
Pharmaceutical excluding COVID-19 Vacc U.S. International	7,114 5,659 12,773	6,818 5,498 12,316	4.3 2.9 3.7	4.3 13.9 8.6	(11.0) (4.9)	13,671 11,514 25,185	13,164 11,153 24,317	3.9 3.2 3.6	3.9 11.9 7.5	(8.7) (3.9)
(0)	12,770	12,010	0.7	0.0	(4.3)	20,100	24,011	0.0	7.0	(0.0)
MedTech (2)										
U.S.	3,351	3,299	1.6	1.6	-	6,576	6,353	3.5	3.5	- ()
International	3,547 6,898	3,679	(3.6)	5.1 3.4	(8.7)	7,293	7,204	2.3	8.0	(6.8)
	6,898	6,978	(1.1)	3.4	(4.5)	13,869	13,557	2.3	5.9	(3.6)
U.S.	12,197	11,919	2.3	2.3	-	23,611	23,030	2.5	2.5	-
International	11,823	11,393	3.8	13.9	(10.1)	23,835	22,603	5.5	13.3	(7.8)
Worldwide	24,020	23,312	3.0	8.0	(5.0)	47,446	45,633	4.0	7.8	(3.8)
U.S.	12,152	11,868	2.4	2.4	-	23,491	22,879	2.7	2.7	-
International	11,324	11,280	0.4	9.8	(9.4)	22,954	22,490	2.1	9.5	(7.4)
Worldwide excluding COVID-19 Vaccine (3	\$ 23,476	23,148	1.4 %	6.0	(4.6)	\$ 46,445	45,369	2.4 %	6.1	(3.7)

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

⁽¹⁾ Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes

⁽²⁾ Previously referred to as Medical Devices

⁽³⁾ Refer to supplemental sales reconciliation schedule

Johnson & Johnson and Subsidiaries

Supplementary Sales Data

(Unaudited; Dollars in Millions)		SE	COND QUARTE	R				SIX MONTHS		
				Percent Change					Percent Change	
	2022	2021	Total	Operations	Currency	2022	2021	Total	Operations	Currency
Sales to customers by										
geographic area										
U.S.	\$ 12,197	11,919	2.3 %	2.3		\$ 23,611	23,030	2.5 %	2.5	-
Europe	6,085	5,668	7.3	20.7	(13.4)	12,109	11,082	9.3	20.1	(10.8)
Western Hemisphere excluding U.S.	1,536	1,367	12.4	14.9	(2.5)	3,018	2,791	8.1	9.9	(1.8)
Asia-Pacific, Africa	4,202	4,358	(3.6)	4.7	(8.3)	8,708	8,730	(0.2)	5.6	(5.8)
International	11,823	11,393	3.8	13.9	(10.1)	23,835	22,603	5.5	13.3	(7.8)
Worldwide	\$ 24,020	23,312	3.0 %	8.0	(5.0)	\$ 47,446	45,633	4.0 %	7.8	(3.8)

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

Johnson-Johnson

			SECOND QUART	ER	
		_		% Change	
	2022	2021	Reported	Operational (1)	Currency
CONSUMER HEALTH SEGMENT (2,3)					
OTC					
US	\$ 663	675	-1.8%	-1.8%	_
Intl	818	752	8.8%	15.9%	-7.1%
WW	1,482	1,426	3.8%	7.5%	-3.7%
SKIN HEALTH / BEAUTY					
US	629	659	-4.5%	-4.5%	-
Intl	497	511	-2.8%	5.1%	-7.9%
WW	1,126	1,170	-3.7%	-0.3%	-3.4%
ORAL CARE					
US	170	165	3.4%	3.4%	-
Intl	224	260	-14.1%	-8.7%	-5.4%
WW	394	426	-7.3%	-4.0%	-3.3%
BABY CARE					
US	88	97	-9.1%	-9.1%	-
Intl	287	290	-1.0%	3.7%	-4.7%
WW	375	387	-3.1%	0.5%	-3.6%
WOMEN'S HEALTH					
US	3	3	8.9%	8.9%	-
Intl	228	227	0.1%	7.2%	-7.1%
WW	230	230	0.2%	7.2%	-7.0%
WOUND CARE / OTHER					
US	133	153	-12.7%	-12.7%	-
Intl	65	64	1.7%	5.2%	-3.5%
WW	197	216	-8.4%	-7.4%	-1.0%
TOTAL CONSUMER HEALTH					
US	1,687	1,751	-3.6%	-3.6%	-
Inti WW	2,118 \$ 3,805	2,103 3,854	0.6% -1.3%	7.3% 2.3%	-6.7% -3.6%
AA AA	\$ 3,805	3,834	-1.3%	2.3%	-3.0%

		REPORT	ED SALES vs. PR	IOR PERIOD (\$MM)	
			SIX MONTHS		
				% Change	
	2022	<u>2021</u>	Reported	Operational (1)	Currency
					<u> </u>
\$	1,333	1,274	4.6%	4.6%	-
	1,609	1,425	12.9%	18.6%	-5.7%
	2,943	2,699	9.0%	12.0%	-3.0%
	1,173	1,293	-9.2%	-9.2%	-
	965	1,040	-7.2%	-1.1%	-6.1%
	2,138	2,333	-8.3%	-5.6%	-2.7%
	313	328	-4.6%	-4.6%	
	447	514	-4.6%	-8.6%	- -4.4%
	760	843	-13.0%	-7.1%	-2.6%
	700	043	-3.7 70	-7.170	-2.070
	173	193	-10.3%	-10.3%	-
	557	583	-4.4%	-0.6%	-3.8%
	730	776	-5.9%	-3.0%	-2.9%
	7	6	8.1%	8.1%	-
	452	446	1.3%	7.7%	-6.4%
	458	452	1.4%	7.7%	-6.3%
	245	268	-8.6%	-8.6%	
	117	125	-6.6%	-4.5%	- -2.1%
	361	393	-8.0%	-7.3%	-0.7%
	001	000	0.070	7.070	0.770
l	3,244	3,362	-3.5%	-3.5%	-
_	4,147	4,133	0.3%	5.7%	-5.4%
\$	7,391	7,495	-1.4%	1.6%	-3.0%

Page 3 of 17

REPORTED SALES vs. PRIOR PERIOD (\$MM)

PHARMACEUTICAL SEGMENT (1.2) 2022 2021 Reported Operational (1) Currency		REPORTED SALES vs. PRIOR PERIOD (\$MM)					
Pharmaceutical Segment (0-3) 2022 2021 Reported Operational (10) Currency				SECOND QUART			
MMUNOLOGY US	(2.2)		_				
S	PHARMACEUTICAL SEGMENT (2,3)	<u>2022</u>	<u>2021</u>	Reported	Operational (1)	Currency	
Initiary 1,559	IMMUNOLOGY						
Name						-	
REMICADE US							
US	WW	4,411	4,231	4.3%	8.1%	-3.8%	
US Exports (**)		201	540	27.49/	27.49/		
Intl						-	
NW SIMPONI / SIMPONI ARIA US 10 290 3.8% 3.8% - 10.0% 10 266 294 9.7% 0.3% - 10.0% 10 266 294 9.7% 0.3% - 10.0% 266 294 9.7% 0.3% - 10.0% 206 584 - 3.0% 2.0% - 5.0% 5.6% 584 - 3.0% 2.0% - 5.0% 5.6% 584 - 3.0% 2.0% - 5.0% 5.0%						5 20/	
SIMPONI / SIMPONI ARIA US							
US		647	888	-21.2%	-25.6%	-1.0%	
Intl		301	200	3 8%	3 8%	_	
STELARA STELARA US						-10.0%	
STELARA US							
Track 1,731		300	364	-3.0 %	2.076	-5.0 /6	
Number 10 10 10 10 10 10 10 1		4 704	4 400	45.70/	45.70/		
TREMEYA 14.3% 18.6% -4.3% TREMEYA US 382 325 17.7% 17.7% -						40.40/	
TREMEYA US 17.7% 17.7% 16.1% 15.5 36.3% 54.6% 16.3% 16.3% 15.5 36.3% 54.6% 16.3%							
Name		2,599	2,274	14.3%	18.6%	-4.3%	
Inti		200	205	47.70/	47.70/		
WW 597 479 24.4% 29.7% -5.3% OTHER IMMUNOLOGY US Intl 3 5 -50.1% -50.1% - INTL 0 1 *						40.00/	
OTHER IMMUNOLOGY US							
US 11		597	479	24.4%	29.7%	-5.3%	
Inti			-	E0.40/	FO 40/		
NW				-50.1%	-50.1%	*	
NFECTIOUS DISEASES US				E0 20/	E0 20/	0.00/	
S		3	,	-59.2%	-39.2%	0.0%	
Number 1,316 1,018 29.3% 42.0% -12.7%		445	444	6 40/	C 40/		
Table Tabl						22.50/	
COVID-19 VACCINE US							
US		1,316	1,018	29.3%	42.0%	-12.7%	
NU 113 114 115		45	51	-11 5%	-11 5%	_	
WW 544 164 * <td></td> <td></td> <td></td> <td>*</td> <td></td> <td>*</td>				*		*	
Section Precious				*	*	*	
S 9 9 -1.7%		044	104				
NT NT NT NT NT NT NT NT		۵	۵	-1 7%	-1 7%	_	
WW 225 262 -14.3% -5.3% -9.0% PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA US 355 368 -3.4% -3.4% - Intl 110 137 -20.2% -10.4% -9.8% WW 464 505 -7.9% -5.3% -2.6% OTHER INFECTIOUS DISEASES US US 6 16 -62.5% -62.5% - Intl 77 71 7.4% 10.9% -3.5%						-9.3%	
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA US 355 368 -3.4% -3.4% -1.0							
US 355 368 -3.4% -3.4%		220	202	14.070	0.070	3.070	
Intl 110 137 -20.2% -10.4% -9.8% WW 464 505 -7.9% -5.3% -2.6% OTHER INFECTIOUS DISEASES US 6 16 -62.5% -62.5% - Intl 77 71 7.4% 10.9% -3.5%		255	200	0.407	2.401		
WW 464 505 -7.9% -5.3% -2.6% OTHER INFECTIOUS DISEASES US Intl 6 16 -62.5% -62.5% - Intl 77 71 7.4% 10.9% -3.5%						- 0.00/	
OTHER INFECTIOUS DISEASES US 6 16 -62.5% -62.5% - Intl 77 71 7.4% 10.9% -3.5%							
US 6 16 -62.5% -62.5% - Intl 77 71 7.4% 10.9% -3.5%		404	505	-1.9%	-5.5%	-2.0%	
Intl		_	40	60.50	60.50		
vv vv 83 88 -5.4% -2.6% -2.8%							
	vv vv	83	88	-5.4%	-∠.0%	-2.8%	

Six Months Six			REPORT		RIOR PERIOD (\$MM)	
\$ 5,354				SIX MONTHS		
\$ 5,354		2022		Damantad		C
3,176 2,984 6.4% 14.9% -8.5% 8,530 8,145 4.7% 7.8% -3.1% 749 1,029 -27.1% -27.1% - 124 150 -17.5% -17.5% - 437 487 -10.3% -6.7% -3.6% 1,310 1,665 -21.4% -20.3% -1.1% 588 545 7.9% 7.9% - 549 601 -8.6% -0.8% -7.8% 1,137 1,146 -0.8% 3.3% -4.1% 3,110 2,827 10.0% 10.0% - 1,777 1,595 11.4% 20.8% -9.4% 4,887 4,422 10.5% 13.9% -3.4% 773 599 29.1% 29.1% - 1,187 897 32.3% 36.6% 4.3% 9 12 -24.8% - - 0 3 -39.0% 79.0% <th></th> <th>2022</th> <th><u>2021</u></th> <th>Reported</th> <th>Operational</th> <th>Currency</th>		2022	<u>2021</u>	Reported	Operational	Currency
3,176 2,984 6.4% 14.9% -8.5% 8,530 8,145 4.7% 7.8% -3.1% 749 1,029 -27.1% -27.1% - 124 150 -17.5% -17.5% - 437 487 -10.3% -6.7% -3.6% 1,310 1,665 -21.4% -20.3% -1.1% 588 545 7.9% 7.9% - 549 601 -8.6% -0.8% -7.8% 1,137 1,146 -0.8% 3.3% -4.1% 3,110 2,827 10.0% 10.0% - 1,777 1,595 11.4% 20.8% -9.4% 4,887 4,422 10.5% 13.9% -3.4% 773 599 29.1% 29.1% - 1,187 897 32.3% 36.6% 4.3% 9 12 -24.8% - - 0 3 -39.0% 79.0% <th></th> <th></th> <th></th> <th></th> <th></th> <th></th>						
3,176 2,984 6.4% 14.9% -8.5% 8,530 8,145 4.7% 7.8% -3.1% 749 1,029 -27.1% -27.1% - 124 150 -17.5% -17.5% - 437 487 -10.3% -6.7% -3.6% 1,310 1,665 -21.4% -20.3% -1.1% 588 545 7.9% 7.9% - 549 601 -8.6% -0.8% -7.8% 1,137 1,146 -0.8% 3.3% -4.1% 3,110 2,827 10.0% 10.0% - 1,777 1,595 11.4% 20.8% -9.4% 4,887 4,422 10.5% 13.9% -3.4% 773 599 29.1% 29.1% - 1,187 897 32.3% 36.6% 4.3% 9 12 -24.8% - - 0 3 -39.0% 79.0% <th>•</th> <th>5 354</th> <th>5 161</th> <th>3 7%</th> <th>3 7%</th> <th>_</th>	•	5 354	5 161	3 7%	3 7%	_
8,530 8,145 4.7% 7.8% -3.1% 749 1,029 -27.1% -27.1% - 124 150 -17.5% -17.5% - 437 487 -10.3% -6.7% -3.6% 1,310 1,665 -21.4% -20.3% -1.1% 588 545 7.9% 7.9% - 549 601 -8.6% -0.8% -7.8% 1,137 1,146 -0.8% 3.3% -4.1% 3,110 2,827 10.0% 10.0% - 1,777 1,595 11.4% 20.8% -9.4% 4,887 4,422 10.5% 13.9% -3.4% 773 599 29.1% 29.1% - 4,187 897 32.3% 36.6% 51.4% -12.8% 1,187 897 32.3% 36.6% -4.3% 9 12 -24.8% -24.8% - 1,737 1,060	•					-8.5%
124 150 -17.5% -17.5% -3.6% 437 487 -10.3% -6.7% -3.6% 1,310 1,665 -21.4% -20.3% -1.1% 588 545 7.9% 7.9% - 549 601 -8.6% -0.8% -7.8% 1,137 1,146 -0.8% 3.3% -4.1% 3,110 2,827 10.0% 10.0% - 1,777 1,595 11.4% 20.8% -9.4% 4,887 4,422 10.5% 13.9% -3.4% 773 599 29.1% 29.1% - 413 298 38.6% 51.4% -12.8% 4,422 10.5% 39.0% 36.6% -4.3% 9 12 -24.8% -24.8% - 0 3 36.6% 51.4% -12.8% 1,737 1,060 63.9% 79.0% -15.1% 2,613 2,016 29.6%	-					-3.1%
124 150 -17.5% -17.5% -3.6% 437 487 -10.3% -6.7% -3.6% 1,310 1,665 -21.4% -20.3% -1.1% 588 545 7.9% 7.9% - 549 601 -8.6% -0.8% -7.8% 1,137 1,146 -0.8% 3.3% -4.1% 3,110 2,827 10.0% 10.0% - 1,777 1,595 11.4% 20.8% -9.4% 4,887 4,422 10.5% 13.9% -3.4% 773 599 29.1% 29.1% - 413 298 38.6% 51.4% -12.8% 4,422 10.5% 39.0% 36.6% -4.3% 9 12 -24.8% -24.8% - 0 3 36.6% 51.4% -12.8% 1,737 1,060 63.9% 79.0% -15.1% 2,613 2,016 29.6%						
124 150 -17.5% -17.5% - 437 487 -10.3% -6.7% -3.6% 1,310 1,665 -21.4% -20.3% -1.1% 588 545 7.9% 7.9% - 549 601 -8.6% -0.8% -7.8% 1,137 1,146 -0.8% 3.3% -4.1% 3,110 2,827 10.0% 10.0% - 1,777 1,595 11.4% 20.8% -9.4% 4,887 4,422 10.5% 13.9% -3.4% 773 599 29.1% 29.1% - 413 298 38.6% 51.4% -12.8% 4,422 10.5% 30.6% -4.3% 9 12 -24.8% -24.8% - - 0 3 -2.3% 36.6% -1.8% - 0 3 -39.0% -39.0% 0.0% 876 956 -8.3%		749	1.029	-27.1%	-27.1%	_
437 487 -10.3% -6.7% -3.6% 1,310 1,665 -21.4% -20.3% -1.1% 588 545 7.9% 7.9% - 549 601 -8.6% -0.8% -7.8% 1,137 1,146 -0.8% 3.3% -4.1% 3,110 2,827 10.0% 10.0% - 1,777 1,595 11.4% 20.8% -9.4% 4,887 4,422 10.5% 13.9% -3.4% 773 599 29.1% 29.1% - 413 298 38.6% 51.4% -12.8% 1,187 897 32.3% 36.6% -4.3% 9 12 -24.8% -24.8% - 0 3 -3.9% -39.0% 0.0% 876 956 -8.3% -8.3% - 1,737 1,060 63.9% 79.0% -15.1% 2,613 2,016 29.6% 3		124			-17.5%	_
588 545 7.9% 7.9% - 1,137 1,146 -8.6% -0.8% -7.8% 1,137 1,146 -0.8% 3.3% -4.1% 3,110 2,827 10.0% 10.0% - 1,777 1,595 11.4% 20.8% -9.4% 4,887 4,422 10.5% 13.9% -3.4% 773 599 29.1% 29.1% - 413 298 36.6% 51.4% -12.8% 1,187 897 32.3% 36.6% -4.3% 9 12 -24.8% -24.8% - 0 3 * * * * 9 15 -39.0% -39.0% 0.0% 876 956 -8.3% -8.3% - 1,737 1,060 63.9% 79.0% -15.1% 2,613 2,016 29.6% 37.6% -8.0% 120 151 -20.4% <t< th=""><th></th><th>437</th><th></th><th>-10.3%</th><th>-6.7%</th><th>-3.6%</th></t<>		437		-10.3%	-6.7%	-3.6%
549 601 -8.6% -0.8% -7.8% 1,137 1,146 -0.8% 3.3% -4.1% 3,110 2,827 10.0% 10.0% - 1,777 1,595 11.4% 20.8% -9.4% 4,887 4,422 10.5% 13.9% -3.4% 773 599 29.1% - - 413 298 38.6% 51.4% -12.8% 1,187 897 32.3% 36.6% -4.3% 9 12 -24.8% -24.8% - 0 3 * * * * 9 15 -39.0% -39.0% 0.0% 876 956 -8.3% -8.3% - - 1,737 1,060 63.9% 79.0% -15.1% 2,613 2,016 29.6% 37.6% -8.0% 120 151 -20.4% -20.4% - 1,001 264 * <th></th> <th>1,310</th> <th>1,665</th> <th>-21.4%</th> <th>-20.3%</th> <th>-1.1%</th>		1,310	1,665	-21.4%	-20.3%	-1.1%
549 601 -8.6% -0.8% -7.8% 1,137 1,146 -0.8% 3.3% -4.1% 3,110 2,827 10.0% 10.0% - 1,777 1,595 11.4% 20.8% -9.4% 4,887 4,422 10.5% 13.9% -3.4% 773 599 29.1% - - 413 298 38.6% 51.4% -12.8% 1,187 897 32.3% 36.6% -4.3% 9 12 -24.8% -24.8% - 0 3 * * * * 9 15 -39.0% -39.0% 0.0% 876 956 -8.3% -8.3% - - 1,737 1,060 63.9% 79.0% -15.1% 2,613 2,016 29.6% 37.6% -8.0% 120 151 -20.4% -20.4% - 1,001 264 * <th></th> <th></th> <th></th> <th></th> <th></th> <th></th>						
549 601 -8.6% -0.8% -7.8% 1,137 1,146 -0.8% 3.3% -4.1% 3,110 2,827 10.0% 10.0% - 1,777 1,595 11.4% 20.8% -9.4% 4,887 4,422 10.5% 13.9% -3.4% 773 599 29.1% - - 413 298 38.6% 51.4% -12.8% 1,187 897 32.3% 36.6% -4.3% 9 12 -24.8% -24.8% - 0 3 * * * * 9 15 -39.0% -39.0% 0.0% 876 956 -8.3% -8.3% - - 1,737 1,060 63.9% 79.0% -15.1% 2,613 2,016 29.6% 37.6% -8.0% 120 151 -20.4% -20.4% - 1,001 264 * <th></th> <th>588</th> <th>545</th> <th>7.9%</th> <th>7.9%</th> <th>-</th>		588	545	7.9%	7.9%	-
3,110 2,827 10.0% 10.0% -9.4% 1,777 1,595 11.4% 20.8% -9.4% 4,887 4,422 10.5% 13.9% -3.4% 773 599 29.1% 29.1% - 413 298 38.6% 51.4% -12.8% 1,187 897 32.3% 36.6% -4.3% 9 12 -24.8% -24.8% - 0 3 * * * * 9 15 -39.0% -39.0% 0.0% 876 956 -8.3% -8.3% - 1,737 1,060 63.9% 79.0% -15.1% 2,613 2,016 29.6% 37.6% -8.0% 120 151 -20.4% -20.4% - 1,001 264 * * * * 454 486 -6.5% 2.2% -8.7% 454 486 -6.5%						-7.8%
1,777 1,595 11.4% 20.8% -9.4% 4,887 4,422 10.5% 13.9% -3.4% 773 599 29.1% 29.1% - 413 298 38.6% 51.4% -12.8% 1,187 897 32.3% 36.6% -4.3% 9 12 -24.8% -24.8% - 0 3 * * * * 9 15 -39.0% -39.0% 0.0% 876 956 -8.3% -8.3% - 1,737 1,060 63.9% 79.0% -15.1% 2,613 2,016 29.6% 37.6% -8.0% 120 151 -20.4% -20.4% - 881 113 * * * * 1,001 264 * * * * 18 19 -7.4% -7.4% - * 454 486		1,137	1,146	-0.8%	3.3%	-4.1%
1,777 1,595 11.4% 20.8% -9.4% 4,887 4,422 10.5% 13.9% -3.4% 773 599 29.1% 29.1% - 413 298 38.6% 51.4% -12.8% 1,187 897 32.3% 36.6% -4.3% 9 12 -24.8% -24.8% - 0 3 * * * * 9 15 -39.0% -39.0% 0.0% 876 956 -8.3% -8.3% - 1,737 1,060 63.9% 79.0% -15.1% 2,613 2,016 29.6% 37.6% -8.0% 120 151 -20.4% -20.4% - 881 113 * * * * 1,001 264 * * * * 18 19 -7.4% -7.4% - * 454 486						
1,777 1,595 11.4% 20.8% -9.4% 4,887 4,422 10.5% 13.9% -3.4% 773 599 29.1% 29.1% - 413 298 38.6% 51.4% -12.8% 1,187 897 32.3% 36.6% -4.3% 9 12 -24.8% -24.8% - 0 3 * * * * 9 15 -39.0% -39.0% 0.0% 876 956 -8.3% -8.3% - 1,737 1,060 63.9% 79.0% -15.1% 2,613 2,016 29.6% 37.6% -8.0% 120 151 -20.4% -20.4% - 881 113 * * * * 1,001 264 * * * * 18 19 -7.4% -7.4% - * 454 486		3.110	2.827	10.0%	10.0%	_
773 599 29.1% 29.1% -12.8% 413 298 38.6% 51.4% -12.8% 1,187 897 32.3% 36.6% -4.3% 9 12 -24.8% -24.8% - 0 3 * * * 9 15 -39.0% -39.0% 0.0% 876 956 -8.3% -8.3% - 1,737 1,060 63.9% 79.0% -15.1% 2,613 2,016 29.6% 37.6% -8.0% 120 151 -20.4% -20.4% - 1,001 264 * * * * 1,001 264 * * * * 18 19 -7.4% -7.4% - * 454 486 -6.5% 2.2% -8.7% 474 478 -3.2% -3.2% - 242 303 -20.3% <						-9.4%
413 298 38.6% 51.4% -12.8% 1,187 897 32.3% 36.6% -4.3% 9 12 -24.8% -24.8% - 0 3 * * * * 9 15 -39.0% -39.0% 0.0% 876 956 -8.3% -8.3% - 1,737 1,060 63.9% 79.0% -15.1% 2,613 2,016 29.6% 37.6% -8.0% 120 151 -20.4% -20.4% - 881 113 * * * * 1,001 264 * * * * * 454 486 -6.5% 2.2% -8.7% 473 505 -6.5% 1.9% -8.4% 724 748 -3.2% -3.2% - 724 748 -3.2% -3.2% - 7965 1,051 -		4,887	4,422	10.5%	13.9%	-3.4%
413 298 38.6% 51.4% -12.8% 1,187 897 32.3% 36.6% -4.3% 9 12 -24.8% -24.8% - 0 3 * * * * 9 15 -39.0% -39.0% 0.0% 876 956 -8.3% -8.3% - 1,737 1,060 63.9% 79.0% -15.1% 2,613 2,016 29.6% 37.6% -8.0% 120 151 -20.4% -20.4% - 881 113 * * * * 1,001 264 * * * * * 454 486 -6.5% 2.2% -8.7% 473 505 -6.5% 1.9% -8.4% 724 748 -3.2% -3.2% - 724 748 -3.2% -3.2% - 7965 1,051 -						
1,187 897 32.3% 36.6% -4.3% 9 12 -24.8% -24.8% - 0 3 -39.0% -39.0% 0.0% 876 956 -8.3% -8.3% - 1,737 1,060 63.9% 79.0% -15.1% 2,613 2,016 29.6% 37.6% -8.0% 120 151 -20.4% -20.4% - 881 113 * * * 1,001 264 * * * 454 486 -6.5% 2.2% -8.7% 473 505 -6.5% 1.9% -8.4% 724 748 -3.2% -3.2% - 724 748 -3.2% -3.2% - 965 1,051 -8.1% -6.1% -2.0% 14 37 -62.5% -62.5% - 160 158 1.3% 5.8% -4.5% <th></th> <th>773</th> <th>599</th> <th>29.1%</th> <th>29.1%</th> <th>-</th>		773	599	29.1%	29.1%	-
9 12 -24.8% -24.8% - 9 15 -39.0% -39.0% 0.0% 876 956 -8.3% -8.3% - 1,737 1,060 63.9% 79.0% -15.1% 2,613 2,016 29.6% 37.6% -8.0% 120 151 -20.4% -20.4% - 881 113 * * * 1,001 264 * * * 454 486 -6.5% 2.2% -8.7% 473 505 -6.5% 1.9% -8.4% 724 748 -3.2% -3.2% - 724 748 -3.2% -3.2% - 965 1,051 -8.1% -6.1% -2.0% 14 37 -62.5% -62.5% - 160 158 1.3% 5.8% -4.5%		413	298	38.6%	51.4%	-12.8%
0 3 *		1,187	897	32.3%	36.6%	-4.3%
0 3 *						
9 15 -39.0% -39.0% 0.0% 876 956 -8.3% -8.3% - 1,737 1,060 63.9% 79.0% -15.1% 2,613 2,016 29.6% 37.6% -8.0% 120 151 -20.4% -20.4% - 881 113 * * * * 1,001 264 * * * * 454 486 -6.5% 2.2% -8.7% 473 505 -6.5% 1.9% -8.4% 724 748 -3.2% -3.2% - 724 748 -3.2% -3.2% - 965 1,051 -8.1% -6.1% -2.0% 14 37 -62.5% -62.5% - 160 158 1.3% 5.8% -4.5%		9	12	-24.8%	-24.8%	-
876 956 -8.3% -8.3% - 1,737 1,060 63.9% 79.0% -15.1% 2,613 2,016 29.6% 37.6% -8.0% 120 151 -20.4% -20.4% - 881 113 * * * * 1,001 264 * * * * 454 486 -6.5% 2.2% -8.7% 473 505 -6.5% 1.9% -8.4% 724 748 -3.2% -3.2% - 242 303 -20.3% -13.4% -6.9% 965 1,051 -8.1% -6.1% -2.0% 14 37 -62.5% -62.5% - 160 158 1.3% 5.8% -4.5%						
1,737 1,060 63.9% 79.0% -15.1% 2,613 2,016 29.6% 37.6% -8.0% 120 151 -20.4% -20.4% - 881 113 * * * * 1,001 264 * * * * 454 486 -6.5% 2.2% -8.7% 473 505 -6.5% 1.9% -8.4% 724 748 -3.2% -3.2% - 724 748 -3.2% -3.2% - 965 1,051 -8.1% -6.1% -2.0% 14 37 -62.5% -6.1% -2.0% 14 37 -62.5% -62.5% - 160 158 1.3% 5.8% -4.5%		9	15	-39.0%	-39.0%	0.0%
1,737 1,060 63.9% 79.0% -15.1% 2,613 2,016 29.6% 37.6% -8.0% 120 151 -20.4% -20.4% - 881 113 * * * * 1,001 264 * * * * 454 486 -6.5% 2.2% -8.7% 473 505 -6.5% 1.9% -8.4% 724 748 -3.2% -3.2% - 724 748 -3.2% -3.2% - 965 1,051 -8.1% -6.1% -2.0% 14 37 -62.5% -6.1% -2.0% 14 37 -62.5% -62.5% - 160 158 1.3% 5.8% -4.5%						
2,613 2,016 29.6% 37.6% -8.0% 120 151 -20.4% -20.4% - 881 113 * * * 1,001 264 * * * * 18 19 -7.4% -7.4% - - 454 486 -6.5% 2.2% -8.7% -8.7% 473 505 -6.5% 1.9% -8.4% 724 748 -3.2% -3.2% - 242 303 -20.3% -13.4% -6.9% 965 1,051 -8.1% -6.1% -2.0% 14 37 -62.5% -62.5% - 160 158 1.3% 5.8% -4.5%		876	956	-8.3%	-8.3%	-
120 151 -20.4% -20.4% - 881 113 * * * * 1,001 264 * * * * * 18 19 -7.4% -7.4% - *		1,737	1,060	63.9%	79.0%	-15.1%
881 113 * <th></th> <th>2,613</th> <th>2,016</th> <th>29.6%</th> <th>37.6%</th> <th>-8.0%</th>		2,613	2,016	29.6%	37.6%	-8.0%
881 113 * <th></th> <th>400</th> <th>454</th> <th>20.40/</th> <th>20.40/</th> <th></th>		400	454	20.40/	20.40/	
1,001 264 * * * 18 19 -7.4% -7.4% - 454 486 -6.5% 2.2% -8.7% 473 505 -6.5% 1.9% -8.4% 724 748 -3.2% -3.2% - 242 303 -20.3% -13.4% -6.9% 965 1,051 -8.1% -6.1% -2.0% 14 37 -62.5% -62.5% - 160 158 1.3% 5.8% -4.5%				-20.4%	-20.4%	*
18 19 -7.4% -7.4% - 454 486 -6.5% 2.2% -8.7% 473 505 -6.5% 1.9% -8.4% 724 748 -3.2% -3.2% - 242 303 -20.3% -13.4% -6.9% 965 1,051 -8.1% -6.1% -2.0% 14 37 -62.5% -62.5% - 160 158 1.3% 5.8% -4.5%				*	*	*
454 486 -6.5% 2.2% -8.7% 473 505 -6.5% 1.9% -8.4% 724 748 -3.2% -3.2% - 242 303 -20.3% -13.4% -6.9% 965 1,051 -8.1% -6.1% -2.0% 14 37 -62.5% -62.5% - 160 158 1.3% 5.8% -4.5%		.,				
454 486 -6.5% 2.2% -8.7% 473 505 -6.5% 1.9% -8.4% 724 748 -3.2% -3.2% - 242 303 -20.3% -13.4% -6.9% 965 1,051 -8.1% -6.1% -2.0% 14 37 -62.5% -62.5% - 160 158 1.3% 5.8% -4.5%		10	10	7 40/	7 40/	
473 505 -6.5% 1.9% -8.4% 724 748 -3.2% -3.2% - 242 303 -20.3% -13.4% -6.9% 965 1,051 -8.1% -6.1% -2.0% 14 37 -62.5% -62.5% - 160 158 1.3% 5.8% -4.5%						-8 7%
242 303 -20.3% -13.4% -6.9% 965 1,051 -8.1% -6.1% -2.0% 14 37 -62.5% -62.5% - 160 158 1.3% 5.8% -4.5%						
242 303 -20.3% -13.4% -6.9% 965 1,051 -8.1% -6.1% -2.0% 14 37 -62.5% -62.5% - 160 158 1.3% 5.8% -4.5%						
242 303 -20.3% -13.4% -6.9% 965 1,051 -8.1% -6.1% -2.0% 14 37 -62.5% -62.5% - 160 158 1.3% 5.8% -4.5%		724	749	-3 2%	-3 2%	_
965 1,051 -8.1% -6.1% -2.0% 14 37 -62.5% -62.5% - 160 158 1.3% 5.8% -4.5%						
14 37 -62.5% -62.5% - 160 158 1.3% 5.8% -4.5%	-					
160 158 1.3% 5.8% -4.5%			•			
160 158 1.3% 5.8% -4.5%		14	37	-62 5%	-62 5%	_

REPORTED SALE	s vs. PRIOR	PERIOD	(\$MM
---------------	-------------	--------	-------

NEUROSCIENCE US

CONCERTA / Methylphenidate US

INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA

RISPERDAL CONSTA US

OTHER NEUROSCIENCE US

WW

Intl

ww

US Intl

ww

Intl

WW

Intl

Intl

ww

ww

Intl

Intl

WW

ERLEADA US Intl ww

IMBRUVICA US Intl

ZYTIGA / abiraterone acetate
US

WW OTHER ONCOLOGY US

WW

ONCOLOGY US Intl Intl WW <u>DARZALEX</u> US

	REPORTED SALES vs. PRIOR PERIOD (\$MM)							
		SIX MONTH						
1 1	-		% Change					
2022	<u>2021</u>	Reported	Operational (1)	Currency				
1,7		7.9%	7.9%	-				
1,7		-8.9%	-1.7%	-7.2%				
3,4	75 3,519	-1.2%	2.7%	-3.9%				
	73 82	-11.3%	-11.3%	-				
	45 250	-1.7%	5.8%	-7.5%				
3	18 332	-4.1%	1.5%	-5.6%				
1,3	52 1,234	9.6%	9.6%	-				
7	49 756	-0.8%	8.1%	-8.9%				
2,1	02 1,989	5.7%	9.0%	-3.3%				
	28 139	-7.7%	-7.7%	-				
	26 173	-27.1%	-19.3%	-7.8%				
2	54 312	-18.4%	-14.1%	-4.3%				
	86 158	17.6%	17.6%	-				
	15 728	-15.5%	-10.2%	-5.3%				
8	00 886	-9.6%	-5.2%	-4.4%				
3,2		14.9%	14.9%	-				
4,7		10.9%	20.8%	-9.9%				
7,9	92 7,105	12.5%	18.4%	-5.9%				
1,9		35.1%	35.1%	-				
1,8		39.7%	52.2%	-12.5%				
3,8	42 2,798	37.3%	43.3%	-6.0%				
4	39 364	20.4%	20.4%	-				
4	12 199	*	*	*				
8	50 563	51.1%	57.2%	-6.1%				
7	19 898	-19.9%	-19.9%	-				
1,2	88 1,342	-4.0%	4.1%	-8.1%				
2,0	08 2,241	-10.4%	-5.6%	-4.8%				

38

1,006

1,044

91

156

248

71

1,130

1,201

44

258

302

-47.0%

-11.0%

-13.1%

-39.4%

-18.0%

691 645 7.3% 7.3% - 362 380 -4.6% 6.3% -10.9% 1,054 1,024 2.9% 6.9% -4.0% 65 72 -8.9% -8.9% - 60 84 -28.0% -19.0% -9.0% 125 155 -19.3% -14.4% -4.9% 102 91 11.8% 11.8% - -4.6% 393 464 -15.2% -17.2% -4.6% -3.6% 393 464 -15.2% -11.6% -3.6% 1,679 1,462 14.9% 14.9% - 2,362 2,073 14.0% 26.9% -12.9% 4,042 3,535 14.3% 21.9% -7.6% 1,021 770 32.6% 32.6% - 965 663 45.5% 61.9% -16.4% 1,986 1,433 38.6% 46.1% -7.5% 233 193			SECOND QUART	TER	
896 842 6.5% -4.8% -8.29 1,734 1,804 -3.9% 0.5% -4.4% 38 35 9.4% 9.4% - 123 127 -2.2% 8.0% -10.29 161 161 0.3% 8.3% -8.0% 691 645 7.3% 7.3% - 691 645 7.3% 7.3% - 691 645 7.3% 7.3% - 802 380 -4.6% 6.3% -10.9% 1,054 1,024 2.9% 6.9% -4.0% 65 72 -8.9% -8.9% - 60 84 -28.0% -19.0% -9.0% 125 155 -19.3% -14.4% -4.9% 102 91 11.8% 11.8% - 292 373 -21.8% -17.2% -4.6% 393 464 -15.2% -11.6% -3.6%				% Change	
837 963 -13.0% -4.8% -8.29 1,734 1,804 -3.9% 0.5% -4.49 38	2022	2021	Reported	Operational (1)	Currency
837 963 -13.0% -4.8% -8.29	906	942	6.50/	6 50/	
1,734 1,804 -3.9% 0.5% -4.4% 38 35 9.4% 9.4% -10.29 161 161 0.3% 8.3% -8.09 691 645 7.3% 7.3% -8.09 1,054 1,024 2.9% 6.3% -10.99 1,054 1,024 2.9% 6.9% -4.09 65 72 -8.9% -8.9% -9.09 125 155 -19.3% -14.4% -4.99 102 91 11.8% 11.8% -17.2% -4.69 393 464 -15.2% -11.6% -3.69 393 464 -15.2% -11.6% -3.69 393 464 -15.2% -11.6% -3.69 393 464 -15.2% -11.6% -3.69 4,042 3,535 14.3% 21.9% -7.69 4,042 3,535 14.3% 21.9% -7.69 1,986 1,433					9 20/
38 35 9.4% 9.4% -10.29 161 161 161 0.3% 8.3% -10.29 161 161 0.3% 8.3% -10.29 691 645 7.3% 7.3% - 362 380 -4.6% 6.3% -10.99 1,054 1,024 2.9% 6.9% -4.09 65 72 -8.9% -8.9% - 60 84 -28.0% -19.0% -9.0 125 155 -19.3% -14.4% -4.99 102 91 11.8% 11.8% - - 292 373 -21.8% -17.2% -4.69 393 464 -15.2% -11.6% -3.69 1,679 1,462 14.9% 14.9% - 2,362 2,073 14.0% 26.9% -12.9% 4,042 3,535 14.3% 21.9% -7.69 965 663 <					
123 127 -2.2% 8.0% -10.29 161 161 0.3% 8.3% -8.09 691 645 7.3% 7.3% -8.0% 362 380 -4.6% 6.3% -10.9% 1,054 1,024 2.9% 6.9% -4.0% 65 72 -8.9% -8.9% -9.0% 60 84 -28.0% -19.0% -9.0% 125 155 -19.3% -14.4% -4.9% 102 91 11.8% 11.8% -7.2% -4.6% 393 464 -15.2% -11.6% -3.69 393 464 -15.2% -11.6% -3.69 1,679 1,462 14.9% 14.9% - -2.362 2,073 14.0% 26.9% -12.9% 4,042 3,535 14.3% 21.9% -7.69 1,021 770 32.6% 32.6% - 1,986 1,433 38.6%	1,734	1,004	-3.570	0.570	-4.470
161 161 0.3% 8.3% -8.0% 691 645 7.3% 7.3% - 362 380 -4.6% 6.3% -10.9% 1,054 1,024 2.9% 6.9% -4.0% 65 72 -8.9% -8.9% - 60 84 -28.0% -19.0% -9.0% 125 155 -19.3% -14.4% -4.99 102 91 11.8% 11.8% - - 292 373 -21.8% -17.2% -4.6% 393 464 -15.2% -11.6% -3.6% 364 -15.2% -11.6% -3.6% 1,679 1,462 14.9% 14.9% - 2,362 2,073 14.0% 26.9% -12.9% 4,042 3,535 14.3% 21.9% -7.6% 1,021 770 32.6% 32.6% 32.6% - 1,986 1,433 38.6% <th>38</th> <th></th> <th></th> <th></th> <th></th>	38				
691 645 7.3% 7.3% - 362 380 -4.6% 6.3% -10.9% 1,054 1,024 2.9% 6.9% -4.0% 65 72 -8.9% -8.9% - 60 84 -28.0% -19.0% -9.0% 125 155 -19.3% -14.4% -4.9% 102 91 11.8% 11.8% - - -9.0% 102 91 11.8% 11.8% - - -4.9% 102 91 11.8% 11.8% - - -9.0% 393 464 -15.2% -11.6% -3.6% 1,679 1,462 14.9% 14.9% - - -2.362 2,073 14.0% 26.9% -12.9% -7.6% 4,042 3,535 14.3% 21.9% -7.6% 1,921 770 32.6% 32.6% - - - - -					-10.2%
362 380 -4.6% 6.3% -10.9% 1,054 1,024 2.9% 6.9% -4.0% 65 72 -8.9% -8.9% - 60 84 -28.0% -19.0% -9.0% 125 155 -19.3% -14.4% -4.99 102 91 11.8% 11.8% - 292 373 -21.8% -17.2% -4.6% 393 464 -15.2% -11.6% -3.6% 393 464 -15.2% -11.6% -3.6% 1,679 1,462 14.9% 14.9% - 2,362 2,073 14.0% 26.9% -12.9% 4,042 3,535 14.3% 21.9% -7.6% 1,021 770 32.6% 32.6% 32.6% - 965 663 45.5% 61.9% -16.4% 1,986 1,433 38.6% 46.1% -7.5% 233 193 <	161	161	0.3%	8.3%	-8.0%
1,054 1,024 2.9% 6.9% -4.0% 65 72 -8.9% -8.9% - 60 84 -28.0% -19.0% -9.0% 125 155 -19.3% -14.4% -4.9% 102 91 11.8% 11.8% - -4.6% 292 373 -21.8% -17.2% -4.6% -3.6% 1,679 1,462 14.9% 14.9% - - -2.362 2,073 14.0% 26.9% -12.9% -7.6% 4,042 3,535 14.3% 21.9% -7.6% 1,021 770 32.6% 32.6% - 965 663 45.5% 61.9% -16.4% 1,986 1,433 38.6% 46.1% -7.5% 233 193 20.6% 20.6% - 218 109 * * * 450 302 49.5% 56.9% -7.4% 4620	691	645	7.3%	7.3%	-
65 72 -8.9% -8.9% -9.0% 60 84 -28.0% -19.0% -9.0% 125 155 -19.3% -14.4% -4.9% 102 91 11.8% 11.8% - 292 373 -21.8% -17.2% -4.6% 393 464 -15.2% -11.6% -3.6% 1,679 1,462 14.9% 14.9% -2.362 2,073 14.0% 26.9% -12.9% 4,042 3,535 14.3% 21.9% -7.6% 1,021 770 32.6% 32.6% -965 663 45.5% 61.9% -16.4% 1,986 1,433 38.6% 46.1% -7.5% 233 193 20.6% 20.6% -7.5% 233 193 20.6% 20.6% -7.5% 248 109 * * * * * * * * * * * * * * * * * * *	362	380	-4.6%	6.3%	-10.9%
60 84 -28.0% -19.0% -9.0% 125 155 -19.3% -14.4% -4.9% 102 91 11.8% 11.8% - 292 373 -21.8% -17.2% -4.6% 393 464 -15.2% -11.6% -3.6% 1,679 1,462 14.9% 14.9% - 2,362 2,073 14.0% 26.9% -12.9% 4,042 3,535 14.3% 21.9% -7.6% 1,021 770 32.6% 32.6% - 965 663 45.5% 61.9% -16.4% 1,986 1,433 38.6% 46.1% -7.5% 233 193 20.6% 20.6% - 218 109 * * * 450 302 49.5% 56.9% -7.4% 349 454 -23.1% -23.1% - - 620 662 -6.3%	1,054	1,024	2.9%	6.9%	-4.0%
125 155 -19.3% -14.4% -4.9% 102 91 11.8% 11.8% - 292 373 -21.8% -17.2% -4.6% 393 464 -15.2% -11.6% -3.6% 1,679 1,462 14.9% 14.9% - 2,362 2,073 14.0% 26.9% -12.9% 4,042 3,535 14.3% 21.9% -7.6% 1,021 770 32.6% 32.6% - - -6.4% -7.6% 1,986 1,433 38.6% 46.1% -7.5% -7.5% 233 193 20.6% 20.6% - - -7.2% 218 109 *	65	72	-8.9%	-8.9%	-
102 91 11.8% 11.8% - 292 373 -21.8% -17.2% -4.6% 393 464 -15.2% -11.6% -3.69 1,679 1,462 14.9% 14.9% - 2,362 2,073 14.0% 26.9% -12.9% 4,042 3,535 14.3% 21.9% -7.69 1,021 770 32.6% 32.6% - 965 663 45.5% 61.9% -16.49 1,986 1,433 38.6% 46.1% -7.59 233 193 20.6% 20.6% - 218 109 * * * 450 302 49.5% 56.9% -7.4% 349 454 -23.1% -23.1% - 620 662 -6.3% 3.6% -9.9% 970 1,116 -13.1% -7.2% -5.9% 19 21 -12.2% -12.2%	60	84	-28.0%	-19.0%	-9.0%
292 373 -21.8% -17.2% -4.69 393 464 -15.2% -11.6% -3.69 1,679 1,462 14.9% 14.9% - 2,362 2,073 14.0% 26.9% -12.9% 4,042 3,535 14.3% 21.9% -7.69 1,021 770 32.6% 32.6% - 965 663 45.5% 61.9% -16.4% 1,986 1,433 38.6% 46.1% -7.59 233 193 20.6% 20.6% - 218 109 * * * 450 302 49.5% 56.9% -7.4% 349 454 -23.1% -23.1% - 620 662 -6.3% 3.6% -9.9% 970 1,116 -13.1% -7.2% -5.9% 19 21 -12.2% -12.2% - 486 542 -10.2% 1.5%	125	155	-19.3%	-14.4%	-4.9%
393 464 -15.2% -11.6% -3.6% 1,679 1,462 14.9% 14.9% - 2,362 2,073 14.0% 26.9% -12.9% 4,042 3,535 14.3% 21.9% -7.6% 1,021 770 32.6% 32.6% - 965 663 45.5% 61.9% -16.4% 1,986 1,433 38.6% 46.1% -7.5% 233 193 20.6% 20.6% - 218 109 * * * * 450 302 49.5% 56.9% -7.4% 349 454 -23.1% -23.1% - 620 662 -6.3% 3.6% -9.9% 970 1,116 -13.1% -7.2% -5.9% 19 21 -12.2% -12.2% - 486 542 -10.2% 1.5% -11.7% 505 563 -10.3%	102	91	11.8%	11.8%	-
1,679 1,462 14.9% 14.9% - 2,362 2,073 14.0% 26.9% -12.9% 4,042 3,535 14.3% 21.9% -7.6% 1,021 770 32.6% 32.6% - 965 663 45.5% 61.9% -16.4% 1,986 1,433 38.6% 46.1% -7.5% 233 193 20.6% 20.6% - 218 109 * * * 450 302 49.5% 56.9% -7.4% 349 454 -23.1% -23.1% - 620 662 -6.3% 3.6% -9.9% 970 1,116 -13.1% -7.2% -5.99 19 21 -12.2% -12.2% - 486 542 -10.2% 1.5% -11.7% 505 563 -10.3% 0.9% -11.2%	292	373	-21.8%	-17.2%	-4.6%
2,362 2,073 14.0% 26.9% -12.9% 4,042 3,535 14.3% 21.9% -7.69 1,021 770 32.6% 32.6% - 965 663 45.5% 61.9% -16.4% 1,986 1,433 38.6% 46.1% -7.59 233 193 20.6% 20.6% - 218 109 * * * 450 302 49.5% 56.9% -7.4% 349 454 -23.1% -23.1% - 620 662 -6.3% 3.6% -9.9% 970 1,116 -13.1% -7.2% -5.9% 19 21 -12.2% -12.2% - 486 542 -10.2% 1.5% -11.7% 505 563 -10.3% 0.9% -11.2%	393	464	-15.2%	-11.6%	-3.6%
4,042 3,535 14.3% 21.9% -7.6% 1,021 770 32.6% 32.6% - 965 663 45.5% 61.9% -16.4% 1,986 1,433 38.6% 46.1% -7.5% 233 193 20.6% 20.6% - 218 109 * * * * 450 302 49.5% 56.9% -7.4% 349 454 -23.1% -23.1% - 620 662 -6.3% 3.6% -9.9% 970 1,116 -13.1% -7.2% -5.9% 19 21 -12.2% -12.2% - 486 542 -10.2% 1.5% -11.7% 505 563 -10.3% 0.9% -11.2%	1,679	1,462	14.9%	14.9%	-
1,021 770 32.6% 32.6% - 965 663 45.5% 61.9% -16.4% 1,986 1,433 38.6% 46.1% -7.5% 233 193 20.6% 20.6% - 218 109 - - - 450 302 49.5% 56.9% -7.4% 349 454 -23.1% -23.1% - 620 662 -6.3% 3.6% -9.9% 970 1,116 -13.1% -7.2% -5.9% 19 21 -12.2% -12.2% - 486 542 -10.2% 1.5% -11.7% 505 563 -10.3% 0.9% -11.2%	2,362	2,073	14.0%	26.9%	-12.9%
965 663 45.5% 61.9% -16.4% 1,986 1,433 38.6% 46.1% -7.5% 233 193 20.6% 20.6% - 218 109 * * * 450 302 49.5% 56.9% -7.4% 349 454 -23.1% -23.1% - 620 662 -6.3% 3.6% -9.9% 970 1,116 -13.1% -7.2% -5.9% 19 21 -12.2% -12.2% - 486 542 -10.2% 1.5% -11.7% 505 563 -10.3% 0.9% -11.2%	4,042	3,535	14.3%	21.9%	-7.6%
1,986 1,433 38.6% 46.1% -7.5% 233 193 20.6% 20.6% - 218 109 - - - 450 302 49.5% 56.9% -7.4% 349 454 -23.1% -23.1% - 620 662 -6.3% 3.6% -9.9% 970 1,116 -13.1% -7.2% -5.9% 19 21 -12.2% -12.2% - 486 542 -10.2% 1.5% -11.7% 505 563 -10.3% 0.9% -11.2%	1,021	770	32.6%	32.6%	-
233 193 20.6% 20.6% - 218 109 * * * * 450 302 49.5% 56.9% -7.4% 349 454 -23.1% -23.1% - 620 662 -6.3% 3.6% -9.9% 970 1,116 -13.1% -7.2% -5.9% 19 21 -12.2% -12.2% - 486 542 -10.2% 1.5% -11.7% 505 563 -10.3% 0.9% -11.2%					-16.4%
218 109 49.5% 56.9% -7.4% 349 454 -23.1% -23.1% -9.9% 620 662 -6.3% 3.6% -9.9% 970 1,116 -13.1% -7.2% -5.9% 19 21 -12.2% -12.2% -11.7% 486 542 -10.2% 1.5% -11.7% 505 563 -10.3% 0.9% -11.2%	1,986	1,433	38.6%	46.1%	-7.5%
450 302 49.5% 56.9% -7.4% 349 454 -23.1% -23.1% - 620 662 -6.3% 3.6% -9.9% 970 1,116 -13.1% -7.2% -5.9% 19 21 -12.2% -12.2% - 486 542 -10.2% 1.5% -11.7% 505 563 -10.3% 0.9% -11.2%	233	193	20.6%	20.6%	-
349 454 -23.1% -23.1% - 620 662 -6.3% 3.6% -9.9% 970 1,116 -13.1% -7.2% -5.9% 19 21 -12.2% -12.2% - 486 542 -10.2% 1.5% -11.7% 505 563 -10.3% 0.9% -11.2%			*	*	*
620 662 -6.3% 3.6% -9.9% 970 1,116 -13.1% -7.2% -5.9% 19 21 -12.2% -12.2% - 486 542 -10.2% 1.5% -11.7% 505 563 -10.3% 0.9% -11.2%	450	302	49.5%	56.9%	-7.4%
620 662 -6.3% 3.6% -9.9% 970 1,116 -13.1% -7.2% -5.9% 19 21 -12.2% -12.2% - 486 542 -10.2% 1.5% -11.7% 505 563 -10.3% 0.9% -11.2%	349	454	-23.1%	-23.1%	_
19 21 -12.2% -12.2% - 486 542 -10.2% 1.5% -11.7% 505 563 -10.3% 0.9% -11.2%					-9.9%
486 542 -10.2% 1.5% -11.7% 505 563 -10.3% 0.9% -11.2%	970	1,116	-13.1%	-7.2%	-5.9%
505 563 -10.3% 0.9% -11.2%	19	21	-12.2%	-12.2%	-
	486	542	-10.2%	1.5%	-11.7%
57 23 * * -	505	563	-10.3%	0.9%	-11.2%
	57	23			-
					-8.4%
130 120 7.5% 14.4% -6.9%	130	120	7.5%	14.4%	-6.9%

rage	Э	Oī	17	

-8.7%

-8.2%

-5.1%

-4.3%

-47.0%

-2.3%

-4.9%

-34.3%

-13.7%

REPORTED	CALEC	DDIAD	DEDIAD	/ CB
REPURIED	SALES VS.	PRIOR	PERIOD	(DININI

REPORTED SALES vs. PRIOR PERIOD	(\$MM ²)

			SECOND QUART	TER				SIX MONTHS		
		_		% Change			_		% Change	
	2022	<u>2021</u>	Reported	Operational (1)	Currency	<u>2022</u>	2021	Reported	Operational (1)	Currency
PULMONARY HYPERTENSION										
US	560	595	-5.8%	-5.8%	_	1,132	1,168	-3.1%	-3.1%	_
Intl	284	275	2.8%	15.3%	-12.5%	563	563	-0.1%	9.6%	-9.7%
WW	843	870	-3.1%	0.9%	-4.0%	1,695	1,731	-2.1%	1.1%	-3.2%
<u>OPSUMIT</u>	040	0.0	0.170	0.570	4.070	1,000	1,101	2.170	1.170	0.270
US	265	290	-8.7%	-8.7%	-	538	562	-4.3%	-4.3%	-
Intl	173	172	0.5%	13.1%	-12.6%	343	351	-2.2%	7.4%	-9.6%
WW	438	463	-5.3%	-0.6%	-4.7%	881	913	-3.5%	0.2%	-3.7%
<u>UPTRAVI</u>										
US	272	268	1.4%	1.4%	-	541	527	2.6%	2.6%	-
Intl	56	45	26.2%	38.3%	-12.1%	112	91	23.5%	33.4%	-9.9%
WW	328	313	4.9%	6.6%	-1.7%	653	618	5.7%	7.1%	-1.4%
OTHER PULMONARY HYPERTENSION										
US	23	36	-36.2%	-36.2%	-	53	78	-32.3%	-32.3%	-
Intl	55	59	-8.1%	4.8%	-12.9%	108	122	-11.7%	-2.0%	-9.7%
WW	78	95	-18.7%	-10.7%	-8.0%	161	200	-19.8%	-13.9%	-5.9%
CARDIOVASCULAR / METABOLISM / OTHER										
US	757	780	-3.0%	-3.0%	7.50/	1,429	1,579	-9.5%	-9.5%	- 70/
Intl	215	241	-10.9%	-3.4%	-7.5%	453	486	-6.9%	-1.2%	-5.7%
WW XARELTO	972	1,021	-4.8%	-3.1%	-1.7%	1,882	2,065	-8.9%	-7.5%	-1.4%
US	000	FCO	7.1%	7.1%		4 447	4.450	2.50/	2.50/	
Intl	609	569	7.1%	7.1%	-	1,117	1,158	-3.5%	-3.5% -	-
WW	609	569	7.1%	7.1%	-	1,117	1,158	-3.5%	-3.5%	-
INVOKANA / INVOKAMET	009	569	7.170	7.170	-	1,117	1,130	-3.5%	-3.5%	-
US	55	96	-42.9%	-42.9%	_	115	183	-37.1%	-37.1%	_
Intl	65	64	2.4%	10.2%	-7.8%	133	127	4.9%	10.6%	-5.7%
WW	120	160	-24.9%	-21.8%	-3.1%	248	310	-19.9%	-17.6%	-2.3%
OTHER						=				,,
US	93	116	-19.5%	-19.5%	-	197	238	-17.2%	-17.2%	-
Intl	150	178	-15.6%	-8.3%	-7.3%	320	360	-11.1%	-5.4%	-5.7%
WW	243	293	-17.2%	-12.7%	-4.5%	517	598	-13.5%	-10.1%	-3.4%
TOTAL PHARMACEUTICAL										
US	7,159	6,869	4.2%	4.2%	-	13,791	13,315	3.6%	3.6%	-
Intl	6,158	5,611	9.8%	22.1%	-12.3%	12,395	11,266	10.0%	19.4%	-9.4%
WW	\$ 13,317	12,480	6.7%	12.3%	-5.6%	\$ 26,186	24,581	6.5%	10.8%	-4.3%

See footnotes at end of schedule

	~ ~			/4
REPORTED	SALES VS.	PRIOR	PERIOD	(SIVIIVI

MEDTECH SEGMENT (2,3,5)

US Intl WW HIPS US Intl WW KNEES US Intl WW

ww

INTERVENTIONAL SOLUTIONS
US
Intl
WW
ORTHOPAEDICS

Intl
WW
TRAUMA
US
Intl
WW
SPINE, SPORTS & OTHER
US
Intl

SECOND QUARTER								
		_		% Change				
	2022	<u>2021</u>	Reported	Operational (1)	Currency			
\$	525	475	10.5%	10.5%	-			
	525	572	-8.1%	1.0%	-9.1%			
	1,049	1,046	0.3%	5.3%	-5.0%			
	1,338	1,323	1.1%	1.1%	-			
	820	904	-9.3%	-0.6%	-8.7%			
	2,157	2,227	-3.1%	0.5%	-3.6%			
	240	233	3.4%	3.4%	-			
	148	159	-6.6%	1.7%	-8.3%			
	388	391	-0.7%	2.7%	-3.4%			
	216	210	2.9%	2.9%	-			
	133	140	-4.6%	3.9%	-8.5%			
	349	350	-0.1%	3.3%	-3.4%			
	464	447	3.9%	3.9%	-			
	232	263	-11.8%	-1.7%	-10.1%			
	696	710	-1.9%	1.8%	-3.7%			
	418	434	-3.7%	-3.7%	-			
	306	343	-10.6%	-2.5%	-8.1%			
	724	777	-6.8%	-3.2%	-3.6%			

REPORTED SALES vs. PRIOR PERIOD (\$M	M)
--------------------------------------	----

	_		% Change	
<u>2022</u>	<u>2021</u>	Reported	Operational (1)	Currency
1,019	909	12.1%	12.1%	-
1,123	1,086	3.4%	10.2%	-6.89
2,141	1,995	7.4%	11.1%	-3.7
2,627	2,572	2.1%	2.1%	-
1,719	1,768	-2.8%	4.2%	-7.0
4,345	4,340	0.1%	3.0%	-2.9
465	442	5.2%	5.2%	-
312	305	2.4%	9.0%	-6.6
777	747	4.1%	6.8%	-2.7
417	395	5.6%	5.6%	-
271	272	-0.4%	6.4%	-6.8
688	667	3.1%	5.9%	-2.8
939	897	4.7%	4.7%	-
505	545	-7.4%	0.3%	-7.7
1,444	1,443	0.1%	3.0%	-2.9
805	838	-3.9%	-3.9%	-
630	646	-2.4%	4.2%	-6.6
1,436	1,484	-3.2%	-0.4%	-2.8

Page 7 of 17

REPORTED SALES vs. PRIOR PERIOD (\$MM) REPORTED SALES vs. PRIOR PERIOD (\$MM)

			SECOND QUART	ER				SIX MONTHS		
				% Change					% Change	
	2022	2021	Reported	Operational (1)	Currency	2022	2021	Reported	Operational (1)	Currency
SURGERY		· <u></u>								
US	992	1,035	-4.1%	-4.1%	-	1,913	1,933	-1.0%	-1.0%	-
Intl	1,458	1,487	-2.0%	5.9%	-7.9%	2,971	2,961	0.3%	6.2%	-5.9%
WW	2,450	2,522	-2.8%	1.8%	-4.6%	4,884	4,894	-0.2%	3.4%	-3.6%
<u>ADVANCED</u>										
US	454	459	-1.1%	-1.1%	-	871	864	0.8%	0.8%	-
Intl	702	708	-0.9%	6.6%	-7.5%	1,431	1,421	0.7%	6.0%	-5.3%
WW	1,156	1,168	-1.0%	3.6%	-4.6%	2,302	2,286	0.7%	4.0%	-3.3%
GENERAL										
US	538	576	-6.4%	-6.4%	-	1,042	1,069	-2.5%	-2.5%	-
Intl	756	779	-3.0%	5.3%	-8.3%	1,540	1,540	0.0%	6.5%	-6.5%
WW	1,294	1,354	-4.5%	0.3%	-4.8%	2,582	2,608	-1.0%	2.8%	-3.8%
VISION										
US	496	467	6.2%	6.2%	-	1,017	939	8.3%	8.3%	-
Intl	745	716	4.0%	13.9%	-9.9%	1,481	1,389	6.6%	15.1%	-8.5%
WW	1,241	1,183	4.9%	10.9%	-6.0%	2,498	2,328	7.3%	12.4%	-5.1%
CONTACT LENSES / OTHER								=	=	
US	374	352	6.6%	6.6%	-	774	723	7.2%	7.2%	- 00/
Intl	519	517	0.4%	11.0%	-10.6%	1,030	1,003	2.7%	11.9%	-9.2%
WW	894	868	2.9%	9.2%	-6.3%	1,804	1,725	4.5%	9.9%	-5.4%
SURGICAL			=	= 40/				10.10	40.407	
US	122	115	5.1%	5.1%	7.00/	243	216	12.1%	12.1%	
Intl	225	199	13.6%	21.5%	-7.9%	451	386	17.0%	23.5%	-6.5%
WW	347	314	10.5%	15.5%	-5.0%	694	602	15.2%	19.4%	-4.2%
TOTAL MEDTECH										
US	3,351	3,299	1.6%	1.6%	_	6,576	6,353	3.5%	3.5%	
Intl	3,547	3,679	-3.6%	5.1%	-8.7%	7,293	7,204	1.2%	8.0%	-6.8%
WW	\$ 6,898	6,978	-1.1%	3.4%	-4.5%	\$ 13,869	13,557	2.3%	5.9%	-3.6%
****	Ψ 0,090 =	0,976	-1.170	3.4 /0	-4.5 /0	¥ 13,009	13,337	2.3 /6	3.5 /0	-3.0 /6
	L					<u> </u>				

Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely

^{*} Percentage greater than 100% or not meaningful (1) Operational growth excludes the effect of translational currency

⁽²⁾ Unaudited

⁽³⁾ Certain prior year amounts have been reclassified to conform to current year product disclosures

⁽⁴⁾ Reported as U.S. sales
(5) Previously referred to as Medical Devices Page 8 of 17

Supplemental Sales Reconciliation (Unaudited)

(Dollars in Millions)

	SECOND QUARTER					SIX MONTHS				
			P	Percent Change				Р	ercent Change	
	2022	2021	Total	Operations	Currency	2022	2021	Total	Operations	Currency
Pharmaceutical										
U.S.	\$ 7,159	6,869	4.2 %	4.2	-	\$ 13,791	13,315	3.6 %	3.6	-
International	6,158	5,611	9.8	22.1	(12.3)	12,395	11,266	10.0	19.4	(9.4)
Worldwide	13,317	12,480	6.7	12.3	(5.6)	26,186	24,581	6.5	10.8	(4.3)
COVID-19 Vaccine										
U.S.	45	51	(11.5)	(11.5)	-	120	151	(20.4)	(20.4)	-
International	499	113	*	*	*	881	113	* -	*	*
Worldwide	544	164	*	*	*	1,001	264	* -	*	*
Pharmaceutical excluding COVID-19 Vaccine										
U.S.	7,114	6,818	4.3	4.3	_	13,671	13,164	3.9	3.9	-
International	5,659	5,498	2.9	13.9	(11.0)	11,514	11,153	3.2	11.9	(8.7)
Worldwide	12,773	12,316	3.7	8.6	(4.9)	25,185	24,317	3.6	7.5	(3.9)
Worldwide										
U.S.	12,197	11,919	2.3	2.3	_	23,611	23,030	2.5	2.5	-
International	11,823	11,393	3.8	13.9	(10.1)	23,835	22,603	5.5	13.3	(7.8)
Worldwide	24,020	23,312	3.0	8.0	(5.0)	47,446	45,633	4.0	7.8	(3.8)
COVID-19 Vaccine										
U.S.	45	51	(11.5)	(11.5)	-	120	151	(20.4)	(20.4)	-
International	499	113	*	*	*	881	113	*	*	*
Worldwide	544	164	*	*	*	1,001	264	*	*	*
Worldwide										
U.S.	12,152	11,868	2.4	2.4	-	23,491	22,879	2.7	2.7	-
International	11,324	11,280	0.4	9.8	(9.4)	22,954	22,490	2.1	9.5	(7.4)
Worldwide excluding COVID-19 Vaccine	\$ 23,476	23,148	1.4 %	6.0	(4.6)	\$ 46,445	45,369	2.4 %	6.1	(3.7)

Note: Columns and rows within tables may not add due to rounding

^{*} Percentage greater than 100% or not meaningful

Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)	SECOND QUARTER							
		Percent						
			Percent			Percent	Increase	
	An	nount	to Sales	An	nount	to Sales	(Decrease)	
Sales to customers	\$	24,020	100.0	\$	23,312	100.0	3.0	
Cost of products sold		7,919	33.0		7,587	32.5	4.4	
Gross Profit		16,101	67.0		15,725	67.5	2.4	
Selling, marketing and administrative expenses		6,226	25.9		6,073	26.1	2.5	
Research and development expense		3,703	15.4		3,394	14.6	9.1	
Interest (income) expense, net		(26)	(0.1)		28	0.1		
Other (income) expense, net		273	1.1		(488)	(2.1)		
Restructuring		85	0.4		56	0.2		
Earnings before provision for taxes on income		5,840	24.3		6,662	28.6	(12.3)	
Provision for taxes on income		1,026	4.3		384	1.7	167.2	
Net earnings	\$	4,814	20.0	\$	6,278	26.9	(23.3)	
Net earnings per share (Diluted)	\$	1.80		\$	2.35		(23.4)	
Average shares outstanding (Diluted)		2,667.9			2,671.6			
Effective tax rate		17.6 %			5.8 %			
Adjusted earnings before provision for taxes and net earnings (1)								
Earnings before provision for taxes on income	\$	8,171	34.0	\$	7,776	33.4	5.1	
Net earnings	\$	6,912	28.8	\$	6,625	28.4	4.3	
Net earnings per share (Diluted)	\$	2.59		\$	2.48		4.4	
Effective tax rate		15.4 %			14.8 %			

⁽¹⁾ See Reconciliation of Non-GAAP Financial Measures.

Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)	SIX MONTHS							
	202	22	20	21	Percent			
	-	Percent		Percent	Increase			
	Amount	to Sales	Amount	to Sales	(Decrease)			
Sales to customers	\$ 47,446	100.0	\$ 45,633	100.0	4.0			
Cost of products sold	15,517	32.7	14,650	32.1	5.9			
Gross Profit	31,929	67.3	30,983	67.9	3.1			
Selling, marketing and administrative expenses	12,164	25.6	11,505	25.2	5.7			
Research and development expense	7,165	15.1	6,572	14.4	9.0			
In-process research and development	610	1.3	-	-				
Interest (income) expense, net	(38)	(0.1)	76	0.2				
Other (income) expense, net	171	0.4	(1,370)	(3.0)				
Restructuring	155	0.3	109	0.2				
Earnings before provision for taxes on income	11,702	24.7	14,091	30.9	(17.0)			
Provision for taxes on income	1,739	3.7	1,616	3.6	7.6			
Net earnings	\$ 9,963	21.0	\$ 12,475	27.3	(20.1)			
Net earnings per share (Diluted)	\$ 3.73		\$ 4.67		(20.1)			
Average shares outstanding (Diluted)	2,669.2		2,674.0					
Effective tax rate	14.9 %		11.5 %					
Adjusted earnings before provision for taxes and net earnings ⁽¹⁾								
Earnings before provision for taxes on income	\$ 16,389	34.5	\$ 16,067	35.2	2.0			
Net earnings	\$ 14,041	29.6	\$ 13,549	29.7	3.6			
Net earnings per share (Diluted)	\$ 5.26		\$ 5.07		3.7			
Effective tax rate	14.3 %		15.7 %					

⁽¹⁾ See Reconciliation of Non-GAAP Financial Measures.

Adjusted Operational Sales Growth SECOND QUARTER 2022 ACTUAL vs. 2021 ACTUAL

Segments

	Consumer Health	Pharmaceutical	MedTech	Total
MOM As Demonted	(4.0)0/	0.70/	(4.4)0/	2.00/
WW As Reported	(1.3)%	6.7%	(1.1)%	3.0%
U.S.	(3.6)%	4.2%	1.6%	2.3%
International	0.6%	9.8%	(3.6)%	3.8%
WW Currency	(3.6)	(5.6)	(4.5)	(5.0)
U.S.	-	-	-	-
International	(6.7)	(12.3)	(8.7)	(10.1)
WW Operational	2.3%	12.3%	3.4%	8.0%
U.S.	(3.6)%	4.2%	1.6%	2.3%
International	7.3%	22.1%	5.1%	13.9%
All Other Acquisitions and Divestitures	0.6	0.1	0.0	0.1
U.S.	0.2	0.2	(0.2)	0.1
International	0.8	0.1	0.2	0.3
WW Adjusted Operational	2.9%	12.4%	3.4%	8.1%
U.S.	(3.4)%	4.4%	1.4%	2.4%
International	8.1%	22.2%	5.3%	14.2%

Note: Percentages are based on actual, non-rounded figures and may not sum

Adjusted Operational Sales Growth SIX MONTHS 2022 ACTUAL vs. 2021 ACTUAL

Segments

	Consumer Health	Pharmaceutical	MedTech	Total
WW As Reported	(1.4)%	6.5%	2.3%	4.0%
U.S.	(3.5)%	3.6%	3.5%	2.5%
International	0.3%	10.0%	1.2%	5.5%
WW Currency	(3.0)	(4.3)	(3.6)	(3.8)
U.S.	-	-	-	-
International	(5.4)	(9.4)	(6.8)	(7.8)
WW Operational	1.6%	10.8%	5.9%	7.8%
U.S.	(3.5)%	3.6%	3.5%	2.5%
International	5.7%	19.4%	8.0%	13.3%
Skin Health / Beauty				
Dr. Ci Labo - Sedona	0.5			0.1
U.S.	0.0			0.0
International	0.9			0.2
All Other Acquisitions and Divestitures	0.1	0.1	0.1	0.1
U.S.	0.2	0.1	(0.1)	0.1
International	0.1	0.0	0.2	0.1
WW Adjusted Operational	2.2%	10.9%	6.0%	8.0%
U.S.	(3.3)%	3.7%	3.4%	2.6%
International	6.7%	19.4%	8.2%	13.6%

Note: Percentages are based on actual, non-rounded figures and may not sum

Second 6	Six Months Ended			
2022	2021	2022	2021	
\$4,814	\$6,278	\$9,963	\$12,475	
1,095	1,202	2,203	2,417	
385	(23)	385	(23)	
-	-	610	-	
128 -	108 14	200	212 (524)	
109	(243)	520	(208)	
70	56	130	102	
276	-	276	-	
268	-	370	-	
-	-	(7)	-	
(313)	(135)	(706)	(248)	
2	-	98	-	
78	(632)	(1)	(654)	
\$6,912	\$6,625	\$14,041	\$13,549	
2,667.9	2,671.6	2,669.2	2,674.0	
\$2.59	\$2.48	\$5.26	\$5.07	
\$2.75		\$5.50		
	2022 \$4,814 1,095 385 - 128 - 109 70 276 268 - (313) 2 78 \$6,912 2,667.9 \$2.59	\$4,814 \$6,278 1,095 1,202 385 (23) 128 108 - 14 109 (243) 70 56 276 - 268 (313) (135) 2 - 78 (632) \$6,912 \$6,625 2,667.9 \$2,671.6 \$2.59 \$2.48	2022 2021 2022 \$4,814 \$6,278 \$9,963 1,095 1,202 2,203 385 (23) 385 - - 610 128 108 200 - 14 - 109 (243) 520 70 56 130 276 - 276 268 - 370 - - (7) (313) (135) (706) 2 - 98 78 (632) (1) \$6,912 \$6,625 \$14,041 2,667.9 2,671.6 2,669.2 \$2.59 \$2.48 \$5.26	

Notes

¹ Acquisition, integration and divestiture related for the six months of 2021 primarily includes the gain on the divestiture of two Pharmaceutical brands outside of the U.S.

² European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company's previously registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices were required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its MedTech operating segments' measures of profit and loss used for making operating decisions and assessing performance which is expected to be completed by the end of 2023.

³ COVID-19 Vaccine related costs include remaining commitments and obligations, including external manufacturing network exit costs and required clinical trial expenses, associated with the Company's modification of its COVID-19 vaccine research program and manufacturing capacity to levels that meet all customer contractual requirements.

⁴ The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.

Q2 QTD - Income Before Tax by Segment*

Dollars in Millions

										Consume	r Health		
		Consumer	Health ¹	Pharmaceu	utical ¹	MedT	ech	Unallo	cated	Separatio	n Costs	Worldwid	e Total
		2022	2021	2022	2021	2022	2021	2022	2021	2022	2021	2022	2021
Reported Income Before Tax by Segment % to Sales	\$	784 20.6%	866 22.5%	4,420 33.2 %	4,294 34.4 %	1,141 16.5%	1,746 25.0%	(237) - 1.0 %	(244) - 1.0 %	(268) - 1.1%	- 0.0%	5,840 24.3 %	6,662 28.6%
Intangible asset amortization expense		100	105	736	842	259	255	-	-	-	-	1,095	1,202
In-process research and development		-	-	-	-	-	-	-	-	-	-	-	-
Litigation related		78	122	36	(81)	271	(64)	-	-	-	-	385	(23)
Loss/(gain) on securities		-	(18)	102	(151)	7	(74)	-	-	-	-	109	(243)
Restructuring related		25	27	23	17	80	64	-	-	-	-	128	108
Acquisition, integration and divestiture related		-	-	-	-	-	14	-	-	-	-	-	14
Medical Device Regulation		-	-	-	-	70	56	-	-	-	-	70	56
COVID-19 Vaccine related costs		-	-	276	-	-	-	-	-	-	-	276	-
Consumer Health separation costs		-	-	-	-	-	-	-	-	268	-	268	-
Other		-	-	-	-	-	-	-	-	-	-	-	-
Adjusted Income Before Tax by Segment	\$	987	1,102	5,593	4,921	1,828	1,997	(237)	(244)			8,171	7,776
% to Sales		25.9%	28.6%	42.0%	39.4%	26.5%	28.6%	-1.0%	-1.0%	0.0%	0.0%	34.0%	33.4%

¹ Prior year income before tax has been reclassified as Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes

^{*}Estimated as of 7/19/2022

Q2 YTD - Income Before Tax by Segment*

Dollars in Millions

	Consumer	Hoalth ¹	Pharmace	utical ¹	MedT	och.	Unallo	rated	Consume Separatio		Worldwide	a Total
	 2022	2021	<u>2022</u>	2021	2022	2021	2022	2021	2022	2021	2022	2021
Reported Income Before Tax by Segment % to Sales	\$ 1,470 19.9%	1,708 22.8%	8,344 31.9%	9,463 38.5%	2,618 18.9%	3,375 24.9 %	(360) - 0.8%	(455) - 1.0%	(370) - 0.8%	0.0%	11,702 24.7%	14,091 30.9 %
Intangible asset amortization expense	194	211	1,496	1,698	513	508	-	-	-	-	2,203	2,417
In-process research and development	-	-	610	-	-	-	-	-	-	-	610	-
Litigation related	78	122	36	(81)	271	(64)	-	-	-	-	385	(23)
Loss/(gain) on securities	0	(20)	496	(114)	24	(74)	-	-	-	-	520	(208)
Restructuring related	39	55	9	37	152	120	-	-	-	-	200	212
Acquisition, integration and divestiture related	-	-	-	(570)	-	46	-	-	-	-	-	(524)
Medical Device Regulation	-	-	-	-	130	102	-	-	-	-	130	102
COVID-19 Vaccine related costs	-	-	276	-	-	-	-	-	-	-	276	-
Consumer Health separation costs	-	-	-	-	-	-	-	-	370	-	370	-
Other	-	-	-	-	-	-	(7)	-	-	-	(7)	-
Adjusted Income Before Tax by Segment	\$ 1,781	2,076	11,267	10,433	3,708	4,013	(367)	(455)			16,389	16,067
% to Sales	 24.1%	27.7%	43.0%	42.4%	26.7%	29.6%	-0.8%	-1.0%	0.0%	0.0%	34.5%	35.2%

¹ Prior year income before tax has been reclassified as Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes

^{*}Estimated as of 7/19/2022

Johnson & Johnson and Subsidiaries GAAP to Non-GAAP Reconciliation \$ in Millions

Quarter to Date

	Second Quarter July 3, 2022 GAAP	Intangible asset amortization	Litigation related	In-process research and development	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Medical Device Regulation	COVID-19 Vaccine Related Costs	Consumer Health separation costs	Consumer Health separation tax related costs	Tax legislation and other tax related	Other	Second Quarter July 3, 2022 Non-GAAP
Cost of products sold Selling, marketing and admin expenses	\$ 7,919 6,226	(1,083)			(17)			(25)	(194)	-			-	6,600 6,220
Research and development expense	3,703							(39)	(110)					3,554
Other (Income) / Expense	273	(12)	(385)		(26)	-	(109)	()	28	(268)				(499)
In-process research and development			,	-	,		, ,			, ,				-
Restructuring	85				(85)									-
Provision for taxes on income	1,026	170	(29)		25	-	25	13	65	44	(2)	(78)		1,259
Net Earnings	4,814	925	414		103	-	84	57	211	224	2	78	-	6,912
	Second Quarter			In-process							Consumer Health	Tax legislation		Second Quarter
	July 4, 2021	Intangible asset		research and	Restructuring	Acquisition, integration and	(Loss)/gain on	Medical Device	COVID-19 Vaccine	Consumer Health	separation tax	and other tax		July 4, 2021
	GAAP	amortization	Litigation related	development	related	divestiture related	securities	Regulation	Related Costs	separation costs	related costs	related	Other	Non-GAAP
Cost of products sold	\$ 7,587	(1,202)			(20)			(20)						6,345
Selling, marketing and admin expenses	6,073							(6)						6,067
Research and development expense	3,394					-		(30)						3,364
Other (Income) / Expense	(488)		23		(32)	(14)	243		-	-	-		-	(268)
In-process research and development				-										-
Restructuring	56		(4)		(56)		(==)							
Provision for taxes on income	384 6,278	163 1,039	(1)		17 91	3 11	(57) (186)	10 46				632 (632)		1,151 6,625
Net Earnings	6,278	1,039	(22)		91	11	(186)	46			-	(632)		6,625
Year to Date														
	Six Months			In-process							Consumer Health	Tax legislation		Six Months
	July 3, 2022	Intangible asset		research and	Restructuring	Acquisition, integration and	(Loss)/gain on	Medical Device	COVID-19 Vaccine	Consumer Health	separation tax	and other tax		July 3, 2022
	July 3, 2022 GAAP	amortization	Litigation related		related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Regulation	Related Costs	Consumer Health separation costs			Other	July 3, 2022 Non-GAAP
Cost of products sold	July 3, 2022 GAAP \$ 15,517		Litigation related	research and				Regulation (47)			separation tax	and other tax	Other	July 3, 2022 Non-GAAP 13,052
Selling, marketing and admin expenses	July 3, 2022 GAAP \$ 15,517 12,164	amortization	Litigation related	research and	related			Regulation (47)	Related Costs (194)		separation tax	and other tax	Other	July 3, 2022 Non-GAAP 13,052 12,152
Selling, marketing and admin expenses Research and development expense	\$ 15,517 12,164 7,165	amortization (2,191)		research and	related (33)		securities	Regulation (47)	Related Costs (194) (110)	separation costs	separation tax	and other tax		July 3, 2022 Non-GAAP 13,052 12,152 6,984
Selling, marketing and admin expenses Research and development expense Other (Income) / Expense	\$ 15,517 12,164 7,165 171	amortization	Litigation related	research and development	related			Regulation (47)	Related Costs (194)		separation tax	and other tax	Other 7	July 3, 2022 Non-GAAP 13,052 12,152
Selling, marketing and admin expenses Research and development expense Other (Income) / Expense In-process research and development	\$ 15,517 12,164 7,165 171 610	amortization (2,191)		research and	(33)		securities	Regulation (47)	Related Costs (194) (110)	separation costs	separation tax	and other tax		July 3, 2022 Non-GAAP 13,052 12,152 6,984
Selling, marketing and admin expenses Research and development expense Other (Income) / Expense	\$ 15,517 12,164 7,165 171	amortization (2,191)	(385)	research and development	related (33)		securities	Regulation (47)	Related Costs (194) (110) 28	separation costs	separation tax related costs	and other tax	7	July 3, 2022 Non-GAAP 13,052 12,152 6,984 (1,093)
Selling, marketing and admin expenses Research and development expense Other (Income) / Expense In-process research and development Restructuring	July 3, 2022 GAAP \$ 15,517 12,164 7,165 171 610 155	amortization (2,191)		research and development	(33) (12) (155)		securities (520)	(47) (12) (71)	Related Costs (194) (110)	separation costs (370)	separation tax	and other tax related		July 3, 2022 Non-GAAP 13,052 12,152 6,984 (1,093)
Selling, marketing and admin expenses Research and development expense Other (Income) / Expense In-process research and development Restructuring Provision for taxes on income	July 3, 2022 GAAP \$ 15,517 12,164 7,165 171 610 155 1,739 9,963		(385)	research and development (610) 138 472	(12) (155) 37		(520)	Regulation (47) (12) (71)	Related Costs (194) (110) 28	separation costs (370)	separation tax related costs - (98) 98	and other tax related 1 (1)	7 (2)	July 3, 2022 Non-GAAP 13,052 12,152 6,984 (1,093) - 2,348 14,041
Selling, marketing and admin expenses Research and development expense Other (Income) / Expense In-process research and development Restructuring Provision for taxes on income	July 3, 2022 GAAP \$ 15,517 12,164 7,165 171 610 155 1,739 9,963 Six Months	amortization (2,191) (12) (12) 338 1,865	(385)	research and development (610) 138 472 In-process	(12) (155) 37 163	divestiture related	(520) 121 399	Regulation (47) (12) (71)	Related Costs (194) (110) 28 65 211	(370) 67 303	separation tax related costs - (98) 98 Consumer Health	and other tax related 1 (1) Tax legislation	7 (2)	July 3, 2022 Non-GAAP 13,052 12,152 6,984 (1,093) - 2,248 14,041 Six Months
Selling, marketing and admin expenses Research and development expense Other (Income) / Expense In-process research and development Restructuring Provision for taxes on income	July 3, 2022 GAAP 5 15,517 12,164 7,165 171 610 155 1,739 9,963 Six Months July 4, 2021	amortization (2,191) (12) (12) (1865 1,865 (1865 1,865 1,865 (1865 1,865 1,865 1,865 (1865 1,865 1,865 1,865 (1865 1,865 1,865 1,865 (1865 1,865 1,865 1,865 (1865 1,865 1,865 1,865 (1865 1,865 1,865 1,865 (1865 1,865 1,865 1,865 (1865 1,865 1,865 1,865 (1865 1,865 1,865 1,865 (1865 1,865 1,865 1,865 (1865 1,865 1,865 1,865 (1865 1,865 1,865 1,865 (1865 1,865 1,865 1,865 (1865 1,865 1,865 1,865 (1865 1,865 1,865 1,865 (1865 1,865 1,865 1,865 (1865 1,865 1,865 1,865 (1865 1,865 1,865 1,865 1,865 (1865 1,865 1,865 1,865 (1865 1,865 1,865 1,865 (1865 1,865 1,865 1,865 (1865 1,865 1,865 1,865 1,865 (1865 1,865 1,865 1,865 1,865 (1865 1,865 1,865 1,865 1,865 1,865 (1865 1,865 1,865 1,865 1,865 1,865 (1865 1,865 1,865 1,865 1,865 1,865 (1865 1,865 1,865 1,865 1,865 1,865 1,865 (1865 1,865	(385) (82) 467	research and development (610) 138 472 In-process research and	related (33) (12) (155) 37 163	divestiture related	(520) 121 399 (Loss)/gain on	(47) (12) (71) 24 106 Medical Device	(110) 28 65 211	(370) 67 303	separation tax related costs (98) 98 Consumer Health separation tax	and other tax related 1 (1) Tax legislation and other tax	7 (2) (5)	July 3, 2022 Non-GAAP 13,052 12,152 6,984 (1,093) - - 2,348 14,041 Six Months July 4, 2021
Selling, marketing and admin expenses Research and development expense Other (Income) / Expense In-process research and development Restructuring Provision for taxes on income Net Earnings	July 3, 2022 GAAP \$ 15,517 12,164 7,165 171 610 155 1,739 9,963 Six Months July 4, 2021 GAAP	2,191 (2,191 338 1,865 Intangible asset amoutization	(385)	research and development (610) 138 472 In-process	related (33) (12) (155) 37 163 Restructuring related	divestiture related	(520) 121 399	Regulation (47) (12) (71) 24 106	Related Costs (194) (110) 28 65 211	(370) 67 303	separation tax related costs - (98) 98 Consumer Health	and other tax related 1 (1) Tax legislation	7 (2)	July 3, 2022 Non-GAAP 13,052 12,152 6,984 (1,093) 2,348 14,041 Six Months July 4, 2021 Non-GAAP
Selling, marketing and admin expenses Research and development expense Other (Income) / Expense In-process research and development Restructuring Provision for taxes on income Net Earnings	July 3, 2022 GAAP \$ 15,517 12,164 7,165 171 610 155 1,739 9,963 Six Months July 4, 2021 GAAP \$ 14,650	amortization (2,191) (12) (12) (1865 1,865 (1865 1,865 1,865 (1865 1,865 1,865 1,865 (1865 1,865 1,865 1,865 (1865 1,865 1,865 1,865 (1865 1,865 1,865 1,865 (1865 1,865 1,865 1,865 (1865 1,865 1,865 1,865 (1865 1,865 1,865 1,865 (1865 1,865 1,865 1,865 (1865 1,865 1,865 1,865 (1865 1,865 1,865 1,865 (1865 1,865 1,865 1,865 (1865 1,865 1,865 1,865 (1865 1,865 1,865 1,865 (1865 1,865 1,865 1,865 (1865 1,865 1,865 1,865 (1865 1,865 1,865 1,865 (1865 1,865 1,865 1,865 (1865 1,865 1,865 1,865 1,865 (1865 1,865 1,865 1,865 (1865 1,865 1,865 1,865 (1865 1,865 1,865 1,865 (1865 1,865 1,865 1,865 1,865 (1865 1,865 1,865 1,865 1,865 (1865 1,865 1,865 1,865 1,865 1,865 (1865 1,865 1,865 1,865 1,865 1,865 (1865 1,865 1,865 1,865 1,865 1,865 (1865 1,865 1,865 1,865 1,865 1,865 1,865 (1865 1,865	(385) (82) 467	research and development (610) 138 472 In-process research and	related (33) (12) (155) 37 163	divestiture related	(520) 121 399 (Loss)/gain on	Regulation (47) (12) (71) 24 106	(110) 28 65 211	(370) 67 303	separation tax related costs (98) 98 Consumer Health separation tax	and other tax related 1 (1) Tax legislation and other tax	7 (2) (5)	July 3, 2022 Non-GAAP 13,052 12,152 6,984 (1,093) - - 2,248 14,041 Six Months July 4, 2021 Non-GAAP
Selling, marketing and admin expenses Research and development expense Other (Income) / Expense In-process research and development Restructuring Provision for taxes on income Net Earnings Cost of products sold Selling, marketing and admin expenses	July 3, 2022 GAAP \$ 15,517 12,164 7,165 171 610 155 1,739 9,963 Six Months July 4, 2021 GAAP \$ 14,650 11,505	2,191 (2,191 338 1,865 Intangible asset amoutization	(385) (82) 467	research and development (610) 138 472 In-process research and	related (33) (12) (155) 37 163 Restructuring related	divestiture related	(520) 121 399 (Loss)/gain on	Regulation (47) (12) (71) 24 106	(110) 28 65 211	(370) 67 303	separation tax related costs (98) 98 Consumer Health separation tax	and other tax related 1 (1) Tax legislation and other tax	7 (2) (5)	July 3, 2022 Non-GAAP 13,052 12,152 6,984 (1,093) - 2,348 14,041 Six Months July 4, 2021 Non-GAAP 12,149 11,494
Selling, marketing and admin expenses Research and development expense Other (Income) / Expense In-process research and development Restructuring Provision for taxes on income Net Earnings Cost of products sold Selling, marketing and admin expenses Research and development expense	July 3, 2022 GAAP \$ 15,517 12,164 7,165 171 610 155 1,739 9,963 Six Months July 4, 2021 GAAP \$ 14,650 11,505 6,572	2,191 (2,191 338 1,865 Intangible asset amoutization	(385) (82) 467 Litigation related	research and development (610) 138 472 In-process research and	related (33) (12) (155) 37 163 (163) (164)	divestiture related	(520) 121 399 (Loss)/gain on securities	Regulation (47) (12) (71) 24 106	(110) 28 65 211	(370) 67 303	separation tax related costs (98) 98 Consumer Health separation tax	and other tax related 1 (1) Tax legislation and other tax	7 (2) (5)	July 3, 2022 Non-GAAP 13,052 12,152 6,984 (1,093) - 2,348 14,041 Six Months July 4, 2021 Non-GAAP 12,149 11,494 6,518
Selling, marketing and admin expenses Research and development expense Other (Income) / Expense In-process research and development Restructuring Provision for taxes on income Net Earnings Cost of products sold Selling, marketing and admin expenses	July 3, 2022 GAAP \$ 15,517 12,164 7,165 171 610 155 1,739 9,963 Six Months July 4, 2021 GAAP \$ 14,650 11,505	2,191 (2,191 338 1,865 Intangible asset amoutization	(385) (82) 467	research and development (610) 138 472 In-process research and	related (33) (12) (155) 37 163 Restructuring related	divestiture related	(520) 121 399 (Loss)/gain on	Regulation (47) (12) (71) 24 106	(110) 28 65 211	(370) 67 303	separation tax related costs (98) 98 Consumer Health separation tax	and other tax related 1 (1) Tax legislation and other tax	7 (2) (5)	July 3, 2022 Non-GAAP 13,052 12,152 6,984 (1,093) - 2,348 14,041 Six Months July 4, 2021 Non-GAAP 12,149 11,494
Selling, marketing and admin expenses Research and development expense Other (Income) / Expense In-process research and development Restructuring Provision for taxes on income Net Earnings Cost of products sold Selling, marketing and admin expenses Research and development expense Other (Income) / Expense	July 3, 2022 GAAP \$ 15,517 12,164 7,165 171 610 155 1,739 9,963 Six Months July 4, 2021 GAAP \$ 14,650 11,505 6,572	2,191 (2,191 338 1,865 Intangible asset amoutization	(385) (82) 467 Litigation related	research and development (610) 138 472 In-process research and	related (33) (12) (155) 37 163 Restructuring related (47) (56)	divestiture related	(520) 121 399 (Loss)/gain on securities	Regulation (47) (12) (71) 24 106	(110) 28 65 211	(370) 67 303	separation tax related costs (98) 98 Consumer Health separation tax	and other tax related 1 (1) Tax legislation and other tax	7 (2) (5)	July 3, 2022 Non-GAAP 13,052 12,152 6,984 (1,093) - 2,348 14,041 Six Months July 4, 2021 Non-GAAP 12,149 11,494 6,518
Selling, marketing and admin expenses Research and development expense Other (Income) / Expense In-process research and development Restructuring Provision for taxes on income Net Earnings Cost of products sold Selling, marketing and admin expenses Research and development expense Other (Income) / Expense In-process research and development	July 3, 2022 GAAP \$ 15,517 12,164 7,165 171 610 155 1,739 9,963 Six Months July 4, 2021 GAAP \$ 14,650 11,505 6,572 (1,370)	2,191 (2,191 338 1,865 Intangible asset amoutization	(385) (82) 467 Litigation related	research and development (610) 138 472 In-process research and	related (33) (12) (155) 37 163 (163) (17) (17) (18) (divestiture related	(520) 121 399 (Loss)/gain on securities	Regulation (47) (12) (71) 24 106	(110) 28 65 211	(370) 67 303	separation tax related costs (98) 98 Consumer Health separation tax	and other tax related 1 (1) Tax legislation and other tax	7 (2) (5)	July 3, 2022 Non-GAAP 13,052 12,152 6,984 (1,093) - 2,348 14,041 Six Months July 4, 2021 Non-GAAP 12,149 11,494 6,518
Selling, marketing and admin expenses Research and development expense Other (Income) / Expense In-process research and development Restructuring Provision for taxes on income Net Earnings Cost of products sold Selling, marketing and admin expenses Research and development expense Other (Income) / Expense In-process research and development Restructuring	July 3, 2022 GAAP \$ 15,517 12,164 7,165 171 610 155 1,739 9,963 Six Months July 4, 2021 GAAP \$ 14,650 11,505 6,572 (1,370) - 109	amortization (2,191) (12) (13) (14) (15) ((385) (82) 467 Litigation related	research and development (610) 138 472 In-process research and	related (33) (12) (155) 37 163 Restructuring related (47) (56)	divestiture related Acquisition, integration and divestiture related (1)	(520) 121 399 (Loss)/gain on securities	Regulation (47) (12) (12) (71) 24 106 Medical Device Regulation (37) (11) (54)	(110) 28 65 211	(370) 67 303	separation tax related costs (98) 98 Consumer Health separation tax	and other tax related 1 (1) Tax legislation and other tax related	7 (2) (5)	July 3, 2022 Non-GAAP 13,052 12,152 6,984 (1,093) - 2,248 14,041 Six Months July 4, 2021 Non-GAAP 12,149 11,494 6,518 (671)

(1) 2021 primarily includes gains on the divestitures of two Pharmaceutical brands outside of the United States.